Just posting this so that it has been posted. I have my doubts it will be relevant to more than a handful - but I could be wrong.
Roxadustat and thyroid-stimulating hormone suppression
Atsuyuki Tokuyama, Hiroyuki Kadoya, Atsushi Obata, Takahiro Obata, Tamaki Sasaki, Naoki Kashihara
Clinical Kidney Journal, Volume 14, Issue 5, May 2021, Pages 1472–1474, doi.org/10.1093/ckj/sfab007
Published: 20 January 2021
Abstract
Hypoxia-inducible factor prolyl-hydroxylase inhibitors belong to a new class of orally administered drugs for treating anemia in patients with chronic kidney disease (CKD). The prevalence of hypothyroidism is disproportionately high in patients with CKD on hemodialysis. We report a rapid suppression of thyroid-stimulating hormone (TSH) and decrease in free triiodothyronine (T3) and free tetraiodothyronine levels after switching from darbepoetin alfa to roxadustat in a hemodialysis patient with hypothyroidism on levothyroxine therapy. This was reversed after stopping roxadustat. Roxadustat has structural similarity with T3 and is a selective activating ligand for thyroid hormone receptor-β possibly suppressing TSH release.
end-stage renal disease, hemodialysis, hypothyroidism, hypoxia-inducible factor prolyl-hydroxylase inhibitor, levothyroxine sodium hydrate, roxadustat
Topic:
• anemia
• hypothyroidism
• hemodialysis
• thyroid hormones
• kidney failure, chronic
• hypoxia
• ligands
• procollagen-proline dioxygenase
• thyrotropin
• thyroxine
• free triiodothyronine
• darbepoetin alfa
Issue Section:
EXCEPTIONAL CASES
Full paper freely accessible here: academic.oup.com/ckj/articl...